NCT00108433

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

Linezolid vs Vancomycin/Cefazolin in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).

Detailed description

Pfizer suspended enrollment on 21 August 2006 as a precautionary measure in light of the mortality imbalance seen in a similar study, and terminated the study on April 6, 2007 due to factors affecting the timeline to completion, such as slow enrollment and inclusion of sufficient evaluable subjects.

Conditions

• Bacteremia
• Gram-Positive Bacterial Infections

Interventions

Type	Name	Description
DRUG	Cefazolin IV
DRUG	Linezolid IV
DRUG	Vancomycin (IV)

Timeline

• Start date: 2005-09-01
• Completion: 2006-09-01
• First posted: 2005-04-18
• Last updated: 2012-08-07
• Results posted: 2012-08-07

Locations

17 sites across 7 countries: United States, Colombia, India, Israel, Italy, Poland, Slovakia